Teclistamab损害经重度预处理骨髓瘤患者的体液免疫:免疫球蛋白补充的重要性
本研究评估Teclistamab对多发性骨髓瘤患者体液免疫的影响,发现其快速耗竭外周血B细胞、消除正常浆细胞并降低多克隆免疫球蛋白水平,且对肺炎链球菌、B型流感嗜血杆菌和SARS-CoV-2疫苗应答严重受损;静脉注射免疫球蛋白与显著降低严重感染风险相关(6个月累积感染发生率5.3% vs 54.8%,P<.001)。
要点
- Teclistamab快速耗竭外周血B细胞并消除正常浆细胞,降低IgG、IgA、IgE和IgM水平且治疗期间无恢复。
- Teclistamab治疗患者对肺炎链球菌、B型流感嗜血杆菌和SARS-CoV-2疫苗应答严重受损。
- 静脉注射免疫球蛋白与Teclistamab治疗患者严重感染风险显著降低相关(6个月累积发生率5.3% vs 54.8%,P<.001)。
核心结论
- Teclistamab诱导严重体液免疫缺陷,免疫球蛋白补充可减轻其影响。
研究设计与样本
- 研究评估接受每周一次皮下注射Teclistamab 1.5 mg/kg的多发性骨髓瘤患者的多克隆免疫球蛋白和B细胞计数,并在部分患者中评估疫苗应答。
主要发现
- Teclistamab快速耗竭多发性骨髓瘤患者外周血B细胞,并在体外试验中消除正常浆细胞。
- Teclistamab降低多克隆免疫球蛋白(IgG、IgA、IgE和IgM)水平,且在接受Teclistamab治疗期间随时间无恢复。
- 与初诊多发性骨髓瘤或复发/难治多发性骨髓瘤患者相比,Teclistamab治疗患者对肺炎链球菌、B型流感嗜血杆菌和SARS-CoV-2疫苗的应答严重受损。
- 静脉注射免疫球蛋白与Teclistamab治疗患者严重感染风险显著降低相关(6个月累积感染发生率:IVIG组5.3% vs 仅观察组54.8%,P<.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Teclistamab and other B-cell maturation antigen (BCMA)-targeting bispecific antibodies (BsAbs) have substantial activity in patients with heavily pretreated multiple myeloma (MM) but are associated with a high rate of infections. BCMA is also expressed on normal plasma cells and mature B cells, which are essential for the generation of a humoral immune response. The aim of this study was to improve the understanding of the impact of BCMA-targeting BsAbs on humoral immunity. The impact of teclistamab on polyclonal immunoglobulins and B cell counts was evaluated in patients with MM who received once-weekly teclistamab 1.5 mg/kg subcutaneously. Vaccination responses were assessed in a subset of patients. Teclistamabinduced rapid depletion of peripheral blood B cells in patients with MM and eliminated normal plasma cells in ex vivo assays. In addition, teclistamab reduced the levels of polyclonal immunoglobulins (immunoglobulin G [IgG], IgA, IgE, and IgM), without recovery over time while receiving teclistamab therapy. Furthermore, response to vaccines against Streptococcus pneumoniae, Haemophilus influenzae type B, and severe acute respiratory syndrome coronavirus 2 was severely impaired in patients treated with teclistamab compared with vaccination responses observed in patients with newly diagnosed MM or relapsed/refractory MM. Intravenous immunoglobulin (IVIG) use was associated with a significantly lower risk of serious infections among patients treated with teclistamab (cumulative incidence of infections at 6 months: 5.3% with IVIG vs 54.8% with observation only [P < .001]). In conclusion, our data show severe defects in humoral immunity induced by teclistamab, the impact of which can be mitigated by the use of immunoglobulin supplementation. This trial was registered at www.ClinicalTrials.gov as #NCT04557098.
引用
- Frerichs KA, Verkleij CPM, Mateos MV, et al. Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation. Blood Adv. 2024. PMID: 38052042. doi:10.1182/bloodadvances.2023011658
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。